Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement
Document Type
Article
Publication Date
1-1-2026
Abstract
Background/Aims: Current guidelines recommend a 2-step approach for identifying advanced fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD), using Fibrosis-4 index (FIB-4) followed by liver stiffness measurement (LSM) via vibration-controlled transient elastography (VCTE). However, some patients may exhibit discordant results. This study evaluates the histological severity and outcomes in patients with discordant FIB-4 and LSM results. Methods: This secondary analysis of the VCTE-Prognosis study included 12,950 patients evaluated for MASLD at 16 tertiary centers, of whom 2,915 underwent liver biopsy. Patients were categorized into four groups based on established FIB-4 (1.3) and LSM (8 kPa) cutoffs. Results: F3–F4 fibrosis was observed in 6.4%, 13.7%, 30.6%, and 62.4% in low-FIB-4-low-LSM (n=6,403), high-FIB-4-low-LSM (n=3,017), low-FIB-4-high-LSM (n=1,363), and high-FIB-4-high-LSM (n=2,167) groups, respectively. During a median follow-up of 47.4 months, 248 patients experienced hepatic decompensation, hepatocellular carcinoma, liver transplantation, or liver-related death. The incidence rates of liver-related events (LREs) were 0.67, 1.19, 2.58, and 21.30 per 1,000 person-years, respectively. Compared to low-FIB-4-low-LSM patients, those with low-FIB-4-high-LSM (adjusted subdistribution hazard ratio [aSHR] 4.12) and high-FIB-4-high-LSM (aSHR 21.38) had a significantly higher risk of LREs, while high-FIB-4-low-LSM patients did not. Similar findings were observed when hepatic decompensation and hepatocellular carcinoma were analyzed separately. Conclusions: Approximately 30% of patients in tertiary centers exhibit discordant FIB-4 and LSM results, with LSM more likely reflecting true severity. While some patients with discordant results may have advanced fibrosis, the overall incidence of LREs remains low.
Keywords
Liver cirrhosis, Liver fibrosis, Metabolic dysfunction-associated steatotic liver disease, Steatotic liver disease
Publication Title
Clinical and Molecular Hepatology
ISSN
2287-2728
DOI
10.3350/cmh.2025.0888
Recommended Citation
Rabbat, Joseph; Yang, Boyu; Lee, Hye Won; Lin, Huapeng; Tsochatzis, Emmanuel; Petta, Salvatore; Bugianesi, Elisabetta; Yoneda, Masato; Zheng, Ming Hua; Hagström, Hannes; Boursier, Jérôme; Calleja, José Luis; Goh, George Boon Bee; Chan, Wah Kheong; Gallego-Durán, Rocio; Sanyal, Arun J.; de Lédinghen, Victor; and Newsome, Philip N., "Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement" (2026). Research Publications (2026 to 2030). 2131.
https://knova.um.edu.my/research_publications_2026_2030/2131
Volume
32
Issue
1
First Page
289
Last Page
304
Publisher
Korean Association for the Study of the Liver